Skip to main navigation Skip to search Skip to main content

HIV/HCV and HIV/HBV Co-infections

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Human immunodeficiency virus (HIV) co-infection accelerates both hepatitis C (HCV) and hepatitis B (HBV) natural history leading to faster progression to and increased incidence of cirrhosis, hepatocellular carcinoma (HCC) and death. HIV/HCV co-infected patients have twice the risk of developing cirrhosis and a sixfold increased risk of liver failure compared with those with HCV alone. Effective treatment of HBV and HCV in HIV co-infected patients increases survival. Treatment responses to TVR do not differ between HIV/HCV co-infected and HCV mono-infected patients. In patients treated with TVR combination treatment, overall safety and tolerability profile was comparable to that previously observed in chronic genotype 1 HCV mono-infected patients. In HIV/HBV co-infected patients, any treatment decision for hepatitis B should take into account the possible impact on HIV and vice-versa. For HIV/HBV co-infected patients, initiation of ART with active anti-HBV coverage is now recommended at any CD4+T-cell count to reduce the risk of liver disease progression.

Original languageEnglish
Title of host publicationMount Sinai Expert Guides
Subtitle of host publicationHepatology
Publisherwiley
Pages78-95
Number of pages18
ISBN (Electronic)9781118748626
ISBN (Print)9781118517345
DOIs
StatePublished - 1 Jan 2014

Keywords

  • boceprevir
  • entecavir
  • human immunodeficiency virus /hepatitis B co-infection
  • human immunodeficiency virus /hepatitis C co-infection
  • lamivudine
  • pegylated interferon
  • ribavirin
  • sustained virologic response
  • telaprevir
  • tenofovir

Fingerprint

Dive into the research topics of 'HIV/HCV and HIV/HBV Co-infections'. Together they form a unique fingerprint.

Cite this